MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2017 International Congress

    Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients

    D. Woitalla, M. Asgharnejad, L. Joeres, J.-C. Schuller, K.R. Chaudhuri (Bochum, Germany)

    Objective: Prospective non-interventional study conducted in routine clinical practice (PD0013; NCT02227355) to compare effectiveness and tolerability of rotigotine+levodopa (RTG+Ldopa) in Parkinson’s disease (PD) patients aged…
  • 2017 International Congress

    Alien Limb Syndrome Induced by a Dopamine Agonist in a Patient with Parkinsonism and Agenesis of the Corpus Callosum

    M. Krause, J. Shou, S. Joy, D. Torres-Russotto (Omaha, NE, USA)

    Objective: To examine the case of a patient with parkinsonism and agenesis of the corpus callosum whose alien limb phenomenology ceased after withdrawal from ropinirole.…
  • 2017 International Congress

    Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis

    E. Dohin, F. Woltering, M. Asgharnejad (Brussels, Belgium)

    Objective: To investigate the value of adding the dopamine agonist (DA) rotigotine (RTG) to low (<400mg/day) or high (≥400mg/day) levodopa (Ldopa) doses in patients with…
  • 2017 International Congress

    Driving license and car accidents in patients with Parkinson’s disease

    M. Tomiyama, T. Ueno, H. Nishijima, T. Kon, R. Haga, Y. Funamizu, A. Arai, C. Suzuki, J. Nunomura, M. Baba (Aomori, Japan)

    Objective: To determine the incidence of and risk factors for car accidents in drivers with Parkinson’s disease (PD). Background: Few studies have addressed traffic accident…
  • 2017 International Congress

    Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation

    K. Schroeder, M. Fenney, D. Gray, T. Rolph, S. Sohur, V. Todaro (New York, NY, USA)

    Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…
  • 2017 International Congress

    Dopamine Agonists and Postural Disorders in Parkinson’s disease

    L. Ameghino, V. Bruno, M. Merello (Buenos Aires, Argentina)

    Objective: To evaluate the relationship between treatment with DA and the development of postural disorders (CC, PS and AC) in patients with PD.  Background: Stood…
  • 2016 International Congress

    Dropped head syndrome in parkinsonism: Two treatable etiologies not to miss

    P. Termsarasab, S.J. Frucht (New York, NY, USA)

    Objective: To report the etiology of treatable head drop in Parkinson's disease (PD): one patient from rotigotine patch and the other two from neck extensor…
  • 2016 International Congress

    Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

    L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

    Objective: To evaluate the accomplishment of a peri-operative dopaminergic replacement protocol established in our centre from 2011 to 2014, and analyse the main factors associated…
  • 2016 International Congress

    The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study

    R.J. Vorovenci, L. Weis, R. Biundo, A. Antonini (Venice, Italy)

    Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…
  • 2016 International Congress

    The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report

    R. González-Maldonado, R. González-Redondo, C.G. DiCaudo (Granada, Spain)

    Objective: To describe the clinical effects of combined natural dopaminergic drugs with conventional levodopa therapy in a PD patient with motor and non-motor complications. Background:…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley